Rijksinstituut voor Volksgezondheid en Milieu (RIVM)
Nationaal Kompas Volksgezondheid


Kort en bondig

De ziekte en de determinanten

Omvang van het probleem

Preventie en zorg

Kijk ook eens bij andere websites:


Bronnen en Literatuur



  • Aaronson NK, Muller M, Cohen PDA, Essink-Bot ML, Fekkes M, Sanderman R, et al.Translation, validation, and norming of the Dutch language version of the SF-36 health survey in community and chronic disease populations. J Clin Epidemiol, 1998; 51: 1055-68.
  • Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Bueno-de-Mesquita HB, Kiemeney L, Tagliabue G, Palli D, Vineis P, Tumino R, Trichopoulou A, Kassapa C, Trichopoulos D, AAnimal foods, protein, calcium and prostate cancer risk: the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2008b; 98(9): 1574-81
  • Andriole GL JR.Screening for prostate cancer. BMJ, 2010; 341: c4538.
  • Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al.Effect of dutasteride on the risk of prostate cancer. N Engl J Med., 2010; 362(13): 1192-202.
  • Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al.Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009 Mar, 2009; 360(13): 1310-9.
  • Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al.Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst, 2012; 104(2): 125-32.
  • Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, et al.Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Registry database [Epub ahead of print]. Eur J Cancer, 2013b;: S0959-8049(13)00842-3.
  • Bangma CH, et al.Bangma CH. Ned Tijdschr Urologie, 2006; 5(5): 148-51.
  • Bartek J, Hamerlik P, Lukas J.On the origin of prostate fusion oncogenes. Nat Genet 2010; 42(8): 647-8
  • Bosetti C, Bertuccio P, Chatenoud L, Negri E, La Vecchia C, Levi F.Trends in mortality from urologic cancers in Europe, 1970-2008. Eur Urol, 2011a; 60(1): 1-15.
  • Bratt O.Hereditary prostate cancer: clinical aspects. J Urol 2002; 168: 906-13.
  • Carter B, Bova G, Beaty T, Steinberg GD, Childs B, Isaacs WB, et al.Hereditary prostate cancer: epidemiological and clinical features. J Urol, 1993; 150: 797-802.
  • Carter BS, Bova GS, Beaty TH, Childs B, Walsh PC.Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992; 89: 3367-71.
  • CDC, Centers for Disease Control and Prevention.Prostate cancer screening http: //www.cdc.gov/cancer/prostate/basic_info/screening.htm (Geraadpleegd 1 december 2010). Atlanta: CDC, 2010.
  • Chan JM, Stampfer MJ, Ma J, Gann PH, Gaziano JM, Giovannucci EL.Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study. Am J Clin Nutr 2001b; 74(4): 549-54
  • Chaussy C, Thuroff S, Rebillard X, Gelet A.Technology insight: High-intensity focused ultrasound for urologic cancers. Nat.Clin.Pract.Urol., 2005; 2(4): 191-198.
  • Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, et al.Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med, 2011; 155(11): 762-71.
  • Coleman MP, Gatta G, Verdecchia A, Esteve J, Sant M, Storm H, et al.EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol, 2003; 14(Suppl 5): v128-49.
  • Crouzet S, Rebillard X, Chevallier D, Rischmann P, Pasticier G, Garcia G, Rouviere O, Chapelon JY, Gelet A.Multicentric oncologic outcomes of high-intensity focused ultrasound for localized prostate cancer in 803 patients. Eur Urol 2010; 58(4): 559-66
  • De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al.Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol, 2013; 10.1016/S1470-2045(13): 70546-1.
  • Debes JD, Tindall DJ.The role of androgens and the androgen receptor in prostate cancer. Cancer Lett, 2002; 187: 1-7.
  • Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, et al.Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ, 2010; 341: c4543.
  • Ferlay J, Parkin DM, Steliarova-Foucher E.Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer, 2010b; 46(4): 765-81.
  • Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al.Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer, 2013; 49(6): 1374-403.
  • Gezondheidsraad.Wet bevolkingsonderzoek: erfelijke prostaatkanker. Den Haag: Gezondheidsraad, 2001i; 2001/01WBO.
  • Giovannucci E, Liu Y, Stampfer MJ, Willett WC.A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15(2): 203-10
  • Heijnsdijk EA, Der Kinderen A, Wever EM, Draisma G, Roobol MJ, Koning HJ de.Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer., 2009; 101(11): 1833-8.
  • Hessels D, Schalken JA.The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol., 2009; 6(5): 255-61.
  • IKNL, Integraal Kankercentrum Nederland. www.cijfersoverkanker.nl, website geraadpleegd in februari 2013.
  • Irwig L, Armstrong B.EUROCARE-2: relevance for assessment of quality of cancer services? Lancet 2000; 355: 427-428.
  • Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer2008; 44(10): 1345-89
  • Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E.Smoking and prostate cancer survival and recurrence. JAMA 2011; 305(24): 2548-55
  • Kiemeney LALM, Witjes JA, Hendrikx AJM, Kil PJM, Vasen HFA.Erfelijk prostaatcarcinoom. Ned Tijdschr Geneeskd 1996; 140: 1068-72.
  • Koh KA, Sesso HD, Paffenbarger RS Jr, Lee IM.Dairy products, calcium and prostate cancer risk. Br J Cancer 2006; 95(11): 1582-5
  • Korfage IJ.Localized prostate cancer and quality of life. Screening, treatment and methodological issues. Rotterdam: Erasmus Medisch Centrum, 2005.
  • La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, et al.Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol, 2010; 21(6): 1323-60.
  • Lesko SM, Rosenberg L, Shapiro S.Family history and prostate cancer risk. Am J Epidemiol 1996; 144: 1041-7.
  • Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C.Leveling of prostate cancer mortality in Western Europe. Prostate, 2004d; 60(1): 46-52.
  • Madalinska JB, Essink-Bot ML, Koning HJ de, Kirkels WJ, Maas PJ van der, Schroder FH.Health-related quality of life in patients with screen-detected versus clinically diagnosed prostate cancer preceding primary treatment . Prostate 2001; 46(2): 87-97.
  • Meer S van der, Kollen BJ, Hirdes WH, Steffens MG, Hoekstra-Weebers JE, Nijman RM, et al.Impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) on prostate-specific antigen (PSA) testing by Dutch general practitioners. BJU Int., 2013; 112(1): 26-31.
  • Mitrou PN, Albanes D, Weinstein SJ, Pietinen P, Taylor PR, Virtamo J, Leitzmann MF.A prospective study of dietary calcium, dairy products and prostate cancer risk (Finland). Int J Cancer 2007; 120(11): 2466-73
  • Monroe KR, Yu MC, Kolonel LN, et al.Evidence of an X-linked or recessive genetic component to prostate cancer risk. Nature Med 1995; 1: 827-829.
  • Narod SA.The Impact of family history on early detection of prostate cancer. Nature Med 1995; 1: 99-101.
  • Nelson WG, Haffner MC, Yegnasubramanian S.Beefing up prostate cancer therapy with performance-enhancing (anti-) steroids. Cancer Cell 2011; 20(1): 7-9
  • NHG, Nederlands Huisartsen Genootschap.Standaard M42 Mictieklachten bij mannen. Utrecht, 2013.
  • NSC, National Screening Committee.National Screening Committee - prostate cancer screening. National Screening Committee Policy Position - May 2005. Prostate cancer. NHS, 2005b.
  • NSC, UK National Screening Committee. Prostate Cancer. 2010.
  • Perez CA, Fair WR, Ihde DC.Carcinoma of the prostate. In: DeVita VT, Hellman S, Rosenberg SA (eds.). Cancer, principles and practice of oncology. Philadelphia: JB Lippencott Company, 1989: 1023-1058.
  • Peters SM, Jovell AJ, Garcia-Altes A, Serra-Prat M.Screening and clinical management of prostate cancer. A cross-national comparison. Int J Technol Assess Health Care, 2001; 17(2): 215-21.
  • Rodriguez C, McCullough ML, Mondul AM, Jacobs EJ, Fakhrabadi-Shokoohi D, Giovannucci EL, Thun MJ, Calle EE.Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. Cancer Epidemiol Biomarkers Prev 2003; 12(7): 597-603
  • Roobol MJ, Kerkhof M, Schröder FH, Cuzick J, Sasieni P, Hakama M, et al.Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol., 2009; 56(4): 584-91.
  • Rossum CTM van, Fransen HP, Verkaik-Kloosterman J, Buurma-Rethans EJM, Ocke MC. Dutch National Food Consumption Survey 2007-2010: Diet of children and adults aged 7 to 69 years. RIVM-rapport nr. 350050006. Bilthoven,2011.
  • Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R.EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer, 2009; 45(6): 931-91.
  • Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al.Screening and prostate-cancer mortality in a randomized European study. N Engl J Med., 2009; 360(13): 1320-8.
  • Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al.Prostate-cancer mortality at 11 years of follow-up. N Engl J Med, 2012; 366(11): 981-90.
  • Schuurman AG, van den Brandt PA, Dorant E, Goldbohm RA.Animal products, calcium and protein and prostate cancer risk in The Netherlands Cohort Study. Br J Cancer 1999; 80(7): 1107-13
  • Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al.The influence of finasteride on the development of prostate cancer. N Engl J Med., 2003b; 349(3): 215-24.
  • UICC, Union for International Cancer Control.TNM Classification of Malignant Tumours, 7e druk. 2009.
  • USPSTF, U.S. Preventive Services Task Force. U.S. Preventive Services Task Force Recommendation Statement. Screening for Prostate Cancer Release Date: May 2012. 2012.
  • Verdecchia A, Guzzinati S, Francisci S, De Angelis R, Bray F, Allemani C, et al.Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer, 2009; 45(6): 1042-66.
  • Walsh PC.Chemoprevention of prostate cancer. N Engl J Med., 2010; 362(13): 1237-8.
  • WCRF/AICR, World Cancer Research Fund & American Institute for Cancer Research.Food, nutrition, physical activity and the prevention of cancer: a global perspective. Washington, 2007; Second expert report.
  • Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA.Campbell-Walsh Urology (9th Edition). Philadelphia: Saunders, 2007.
  • Whittemore AS, Wu AH, Kolonel LN, et al.Family history and prostate cancer risk black, white and asian men in the United States and Canada. Am J Epidemiol 1995b; 141: 732-740.
  • Witjes JA.Richtlijnen voor controle bij patiënten met prostaatcarcinoom. Nederlands Tijdschrift voor Geneeskunde, 2002; 146(8): 360-362.
  • Witte JS.Personalized prostate cancer screening: improving PSA tests with genomic information. Sci Transl Med 2010; 2(62): 62ps55
  • Zu K, Giovannucci E.Smoking and aggressive prostate cancer: a review of the epidemiologic evidence. Cancer Causes Control 2009; 20(10): 1799-810

Begrippen en afkortingen


Centers for Disease Control and Prevention
URL: http://www.cdc.gov/
European Study of Screening for Prostate Cancer
Europese unie
De 15 landen die vóór 1 april 2004 de Europese Unie vormden
België, Denemarken, Duitsland, Finland, Frankrijk, Griekenland, Ierland, Italië, Luxemburg, Nederland, Oostenrijk, Portugal, Spanje, Verenigd Koninkrijk, Zweden.
De 27 landen die van 1 januari 2007 tot en met 1 juli 2013 de Europese Unie vormden.
België, Bulgarije, Cyprus, Denemarken, Duitsland, Estland, Finland, Frankrijk, Griekenland, Hongarije, Ierland, Italië, Letland, Litouwen, Luxemburg, Malta, Nederland, Oostenrijk, Polen, Portugal, Roemenië, Slovenië, Slowakije, Spanje, Tsjechië, Verenigd Koninkrijk, Zweden.
International Classification of Diseases, tenth revision
International Classification of Diseases, ninth revision
Integraal Kankercentrum Nederland
Luteinising hormone releasing hormone
Nederlands huisartsengenootschap
URL: http://www.nhg.org
Prostaat specifiek antigeen
Relatieve 5-jaarsoverleving
Relatieve 5-jaarsoverleving
De kans dat iemand vijf jaar na diagnose van een bepaalde ziekte niet aan die ziekte overleden is. Deze kans wordt geschat door deling van de geobserveerde overleving (onafhankelijk van doodsoorzaak) van de patiëntengroep gedeeld door de verwachte overleving van een groep met een zelfde leeftijds- en geslachtsopbouw uit de algemene populatie (op basis van sterftetafels van de algemene bevolking).
Tumor, Node, Metastase
Anatomische classificatie van tumoren, gebaseerd op de grootte van de primaire tumor, de aanwezigheid van aangedane lymfknopen en de aanwezigheid van eventuele metastasen. De classificatie is ontwikkeld door de International Union Against Cancer (UICC).


Het aantal nieuwe gevallen van of nieuwe personen met een bepaalde ziekte in een bepaalde periode, absoluut of relatief.
Het vergelijkbaar maken van cijfers (bijvoorbeeld sterftecijfers) die betrekking hebben op verschillende jaren of populaties, door rekening te houden met verschillen in bijvoorbeeld leeftijdsverdeling. Een veel gebruikte methode is zogenaamde 'directe standaardisatie', die de leeftijdsspecifieke cijfers van een populatie (de 'indexpopulatie') toepast op de leeftijdsverdeling van een gekozen 'standaardpopulatie'.